Table 2. Additional Outcomes at Week 52.
| Characteristic | IAI Plus Sham PDT (n = 157) |
IAI Plus Active PDT (n = 161) |
P Value |
|---|---|---|---|
| Proportion of participants avoiding a moderate vision loss of ≥15 ETDRS letters at week 52, %a | 97.5 | 96.9 | .74b |
| Difference (95% CI), % | 0.6 (–3.1 to 4.3) | ||
| Proportion of participants with no ICG leakage from polypoidal lesions at week 52, % | 81.7 | 88.9 | NA |
| Mean area of polypoidal lesions,c mm2 | NA | ||
| Baseline | 0.21 | 0.19 | |
| Week 52 | 0.07 | 0.08 | |
| Difference, baseline to week 52, % | –65.9 | –60.9 | |
| Proportion of participants with complete absence of polypoidal lesions on ICG at week 52, %d | 38.9 | 44.8 | NA |
| Difference (95% CI), % | –6.0 (–17.8 to 5.9) | .32b | |
Abbreviations: ETDRS, Early Treatment Diabetic Retinopathy Study; IAI, intravitreal aflibercept injection; ICG, indocyanine green; PDT, photodynamic therapy.
a
Last observation carried forward full analysis set.
b
Cochran-Mantel-Haenszel.
c
Observed cases, full analysis set.
d
Observed cases, safety analysis set.